ClinicalTrials.gg
RecruitingNCT06291194Updated Apr 8, 2024

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

A Phase 3 interventional study of AJU-S56 5% and Placebo Group(Vehicle) in Dry Eye Syndromes, sponsored by AJU Pharm Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by AJU Pharm Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Feb 2024).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.

Planned enrollment
2nd of 52
396 · median 99
Started
2023
with 5 others
Phase 3
16 of 58
1 open now
Registered
47th of 58
by date
Lead sponsor
2 of 58
AJU Pharm Co., Ltd.

Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 2nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2023, is one of 16 in phase 3, and was the 47th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

Keywords

  • Dry eye
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female who over 19 years old
  • Moderate to Severe Dry Eye Disease Patients
  • Must meet all criteria listed below at least in one eye or both eyes.

    1. TCSS (National eye institute (NEI) scale)≥ 4
    2. Ocular discomfort score (ODS) ≥ 3
    3. Schirmer test(without anesthesia) ≤ 10mm in 5 mins
    4. Tear break-up time ≤ 6 secs
  • Written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Those who have eye disease not related to dry eye syndrome
  • Those who have worn contact lenses before 1week Screening visit or have to wear contact lenses or need to wear contact lenses during study period
  • Those who have medical history with intraocular surgery 12months before screening visit
  • Use of , beta blocker and anticholinergic agent within 4 weeks
  • Participation in other studies within 4weeks of screening visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Test group(AJU-S56 5%)

    QID(4 times in a day) for 24 Weeks after Randomization

    Drug: AJU-S56 5%

  • Placebo comparator
    Placebo group(Vehicle)

    QID(4 times in a day) for 24 Weeks after Randomization

    Drug: Placebo Group(Vehicle)

Interventions

  • DrugAJU-S56 5%

    After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

    Also known as: Test Group

  • DrugPlacebo Group(Vehicle)

    After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Total corneal staining score (TCSS)

    TCSS ≥4 at baseline (Total Max score : 15)

    Time frame: WEEK 4, 8, 12

Secondary outcomes

  1. LGCSS

    Lissamine Green Conjunctival Staining Score(Total score : 0\~18)

    Time frame: WEEK 4, 8, 12

  2. TFBUT

    Tear Film Break Up Time

    Time frame: WEEK 4, 8, 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2024, 6 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 6 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 4, 2024
StartActual
Nov 10, 2023
Primary completionEst.
May 2024
CompletionEst.
May 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06291194
Collaborators
GL Pharm Tech Corporation
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Nov 10, 2023
Primary completion
May 2024 (estimated)
Completion
May 2024 (estimated)
Last update
Apr 8, 2024

Study contacts

JUNNGMIN LEE
Contact
ajuf13001@ajupharm.co.kr
+82-02-2630-0700

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion